Ceftazidime–Avibactam Monotherapy Yields Similar 30-Day Mortality to Combination Regimens
A secondary meta-analysis shows ceftazidime–avibactam monotherapy achieves 30-day survival comparable to combination therapy in adults with carbapenem-resistant Gram-negative bacterial infections.










